AED evaluated
| |
Imepitoin
| | |
2
nd
AED
|
-
|
-
|
-
|
PB (11 dogs) or Primidone (6 dogs)
|
3
rd
AED
|
-
|
-
|
-
|
-
|
4
th
AED
|
-
|
-
|
-
|
-
|
No of dogs
|
After exclusion: 64
|
First part: 127
|
12
|
17
|
|
Before exclusion: 93
|
Second part (follow up): 100 (from the 127)
| | |
Period of treatment (months)
|
5
|
6
|
mean, 7.7 ± 0.7
|
mean, 5.6 ± 0.7
|
Dose of AED(s) (mg/kg)
|
10-30 PO BID
|
High dose group: 30 PO BID
|
5 PO BID for 1 week and then increased to 10–30 PO BID
|
Imepitoin: mean, 7.7 ± 0.7;
|
| |
Low dose: 1 PO BID [during the follow up all the 100 (53 from the previous high dose group and 47 from the low-dose) dogs were treated with the high dose only]
| |
PB: 6–23 PO SID; Primidone: 25–53 PO SID
|
Pre-treatment SF (seizures/month)
|
2.3 (recorded over a period of 1.5 m)
|
High dose group: mean, 2.9
|
median, 1.6 (recorded over a period of approx. 9 m)
|
median, 1.9 (recorded over a period of mean 1.6 years)
|
| |
Low dose group: mean, 2
| | |
Post-treatment SF (seizures/month)
|
1.1
|
High dose group: mean, 2.2
|
median, 0.72
|
median, 2
|
| |
Low dose group: mean, 1.8
| | |
| |
(For the follow up study: NA)
| | |
No of dogs that were failures
|
-
|
Unclear
|
3/12 (25%)
|
6/17 (35%)
|
No of dogs with >0% - <50% reduction in SF
|
-
|
Unclear
|
4/12 (33%)
|
4/17 (24%)
|
No of dogs with ≥50% - <100% reduction in SF
|
After exclusion: 18/64 (28%)
|
Unclear
|
4/12 (33%)
|
6/17 (35%)
|
|
Before exclusion: 22/93 (24%)
| | | |
No of dogs with 100% reduction in SF
|
After exclusion: 30/64 (47%)
|
First Part: High dose group: 44/127 (35%); Low dose: 6/127 (5%)
|
1/12 (8%)
|
1/17 (6%)
|
|
Before exclusion:31/93 (33%)
|
Follow-up: High-high dose group: 19/53 (35%) and Low-high dose group: 24/47 (50%)
| | |
No of dogs with >30% reduction in SF
|
-
|
As above
|
9/12 (75%)
|
11/17 (65%)
|
95% CI successfully treated cases
|
After exclusion: 64% - 86%
|
Follow-up: 25-46% and 36-63% (but only for the seizure free dogs)
|
13% - 69%
|
18% - 64%
|
|
Before exclusion: 47% - 67%
| | | |
Overall evidence for/against recommending the use of an AED
|
Good evidence for recommending the use of imepitoin as a monotherapy AED.
|
Insufficient evidence for recommending the use of imepitoin as an adjunct AED.
|